Sign In
Buy RIGL
Rigel Pharmaceuticals Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.740 |
| EPS actual | $0.440 |
| EPS Surprise | -40.54% |
| Revenue estimate | 62.396M |
| Revenue actual | 58.818M |
| Revenue Surprise | -5.73% |
| Release date | Mar 03, 2026 |
| EPS estimate | $1.33 |
| EPS actual | $1.14 |
| EPS Surprise | -14.29% |
| Revenue estimate | 68.702M |
| Revenue actual | 69.802M |
| Revenue Surprise | 1.60% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.93 |
| EPS actual | $1.46 |
| EPS Surprise | 56.99% |
| Revenue estimate | 68.424M |
| Revenue actual | 69.462M |
| Revenue Surprise | 1.52% |
| Release date | Aug 05, 2025 |
| EPS estimate | $1.97 |
| EPS actual | $3.28 |
| EPS Surprise | 66.50% |
| Revenue estimate | 62.307M |
| Revenue actual | 101.685M |
| Revenue Surprise | 63.20% |
Last 4 Quarters for Rigel Pharmaceuticals
Below you can see how RIGL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 05, 2025 |
| Price on release | $24.24 |
| EPS estimate | $1.97 |
| EPS actual | $3.28 |
| EPS surprise | 66.50% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $21.01 |
| Jul 31, 2025 | $21.06 |
| Aug 01, 2025 | $21.91 |
| Aug 04, 2025 | $22.67 |
| Aug 05, 2025 | $24.24 |
| Aug 06, 2025 | $29.81 |
| Aug 07, 2025 | $30.44 |
| Aug 08, 2025 | $31.70 |
| Aug 11, 2025 | $33.46 |
| 4 days before | 15.37% |
| 4 days after | 38.04% |
| On release day | 22.98% |
| Change in period | 59.26% |
| Release date | Nov 04, 2025 |
| Price on release | $28.38 |
| EPS estimate | $0.93 |
| EPS actual | $1.46 |
| EPS surprise | 56.99% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $29.40 |
| Oct 30, 2025 | $31.62 |
| Oct 31, 2025 | $31.58 |
| Nov 03, 2025 | $30.65 |
| Nov 04, 2025 | $28.38 |
| Nov 05, 2025 | $37.85 |
| Nov 06, 2025 | $36.12 |
| Nov 07, 2025 | $35.19 |
| Nov 10, 2025 | $34.55 |
| 4 days before | -3.47% |
| 4 days after | 21.74% |
| On release day | 33.37% |
| Change in period | 17.52% |
| Release date | Mar 03, 2026 |
| Price on release | $33.02 |
| EPS estimate | $1.33 |
| EPS actual | $1.14 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| Feb 25, 2026 | $34.62 |
| Feb 26, 2026 | $35.71 |
| Feb 27, 2026 | $34.74 |
| Mar 02, 2026 | $34.62 |
| Mar 03, 2026 | $33.02 |
| Mar 04, 2026 | $29.63 |
| Mar 05, 2026 | $29.52 |
| Mar 06, 2026 | $28.87 |
| Mar 09, 2026 | $28.07 |
| 4 days before | -4.62% |
| 4 days after | -14.99% |
| On release day | -10.27% |
| Change in period | -18.92% |
| Release date | May 05, 2026 |
| Price on release | $28.09 |
| EPS estimate | $0.740 |
| EPS actual | $0.440 |
| EPS surprise | -40.54% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $29.22 |
| Apr 30, 2026 | $28.90 |
| May 01, 2026 | $29.40 |
| May 04, 2026 | $29.54 |
| May 05, 2026 | $28.09 |
| May 06, 2026 | $26.67 |
| May 07, 2026 | $26.24 |
| May 08, 2026 | $26.04 |
| May 11, 2026 | $26.20 |
| 4 days before | -3.87% |
| 4 days after | -6.73% |
| On release day | -5.06% |
| Change in period | -10.34% |
Rigel Pharmaceuticals Earnings Call Transcript Summary of Q1 2026
Rigel reported a strong start to 2026 with Q1 net product sales of $54.9M (up 26% YoY) driven by TAVALISSE ($37.3M, +31% YoY), REZLIDHIA ($8.0M, +31% YoY) and GAVRETO ($9.6M, +7% YoY). Total Q1 revenue was $58.8M including $3.9M collaboration revenue. Management reiterated full-year 2026 guidance of $275M–$290M total revenue (including $255M–$265M net product sales) and affirmed the company remains on track to achieve net income profitability for 2026. Key near-term clinical focus is R289 (dual IRAK1/4 inhibitor) in transfusion-dependent, lower‑risk MDS: Phase Ib dose expansion is enrolling, topline dose‑expansion data are expected by year-end 2026, and a potential registration discussion with the FDA is planned after dose selection. Rigel continues to pursue late-stage in‑licensing/acquisitions in hematology/oncology to support launches through 2028 while prioritizing financial discipline. Corporate updates: Lilly will terminate the RIPK1 collaboration (effective June 15, 2026) and Rigel regained program rights; Rigel restructured debt to a $40M revolving credit facility (option to expand to $60M) and drew $8M. Cash and short‑term investments were $146.7M at quarter end. Primary near‑term investor catalysts: Q2 sequential sales recovery (seasonal demand improvement observed in March), year‑end R289 topline data and any late‑stage in‑license or acquisition announcements.
